For the first time, scientists obtained high-definition images of glucagon-like peptide-1 receptors, enabling future research into treatments for type 2 diabetes, according to a study published in Nature Communications.
For the first time, scientists have obtained high-definition images of glucagon-like peptide-1 receptors (GLP1Rs), enabling future research into treatments for type-2 diabetes (T2D), according to a study published in Nature Communications.
GLP1Rs can be found in insulin-producing beta cells in the pancreas and in brain neurons, but their small size makes them difficult for scientists to visualize. Their presence in the pancreas encourages the release of more insulin, curbs appetite, and stops the liver from producing excess glucose. For these reasons, GLP1Rs can help to reduce blood sugar levels, according to a news release.
In the study, researchers present LUXendin645, “a far-red florescent GLP1R antagonistic peptide label [that produces] intense and specific membrane labeling throughout live and fixed tissue.” Previously, visualization of GLP1R was limited to genetic manipulation, using probes to stimulate receptor activation, or antibody detection.
Through the use of LUXendin645 and LUXendin651, the researchers were able to describe “islet, brain and hESC [human embryonic stem cell]—derived β-like cell GLP1R expression patterns, reveal higher-order GLP1R organization including membrane nanodomains, and track single receptor subpopulations.”
They state, “Our super-resolution compatible labeling probes allow visualization of endogenous GLP1R and provide insight into class B GPCR [G protein-couple receptor] distribution and dynamics both in vitro and in vivo.”
Researchers used various techniques to reach their conclusions, including in vivo experimentation of the protein in mice, synthesizing marker compounds, immunostaining, and conducting microscopy using super-resolution.
Specifically, the study yielded the following conclusions:
“Our data…demonstrate an increase in sensitivity compared to other approaches capable of detecting native GLP1R protein,” researchers said. “These experiments provide the first super-resolution characterization of a class B GPCR and suggest a degree of complexity not readily appreciated with previous approaches.”
Reference:
Ast J, Arvaniti A, Fine NHF, et al. Super-resolution microscopy compatible fluorescent probes reveal endogenous glucagon-like peptide-1 receptor distribution and dynamics. Nat Commun. 2020;11(1):467. doi: 10.1038/s41467-020-14309-w.
Exploring Pharmaceutical Innovations, Trust, and Access With CVS Health's CMO
July 11th 2024On this episode of Managed Care Cast, we're talking with the chief medical officer of CVS Health about recent pharmaceutical innovations, patient-provider relationships, and strategies to reduce drug costs.
Listen
How Can Employers Leverage the DPP to Improve Diabetes Rates?
February 15th 2022On this episode of Managed Care Cast, Jill Hutt, vice president of member services at the Greater Philadelphia Business Coalition on Health, explains the Coalition’s efforts to reduce diabetes rates through the Diabetes Prevention Program (DPP).
Listen
Team-Based CINEMA Program Targets SDOH and Precision Care in Diabetes
December 20th 2024Ian Neeland, MD, discusses the CINEMA program's impact on addressing social determinants of health (SDOH) in Ohio and the importance of precision risk tests to reduce cardiovascular metabolic disease risk.
Read More